유방암 근접방사선치료 시장 규모, 점유율, 동향 분석 보고서 : 기술별, 제품별, 지역별, 부문별 예측(2025-2030년)

Breast Cancer Brachytherapy Market Growth & Trends:

The global breast cancer brachytherapy market size is estimated to reach USD 1.3 billion by 2030, expanding at a CAGR of 6.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of breast cancer is expected to accelerate market growth. For instance, the Breastcancer.org reported that as of January 2020, there were more than 3.5 million women suffering from breast cancer in the U.S.

In addition, the rising adoption of brachytherapy by academic medical centers, oncology centers, and hospitals is expected to boost the market growth. For instance, in October 2018, Navicent Health adopted the Xoft Axxent Electronic Brachytherapy (eBx) System developed by iCAD, Inc. for the treatment of breast cancer in Georgia. Furthermore, in October 2018, SUNY Upstate Medical University also adopted the Xoft Axxent Electronic Brachytherapy (eBx) System to provide treatment for early-stage breast cancer.

Moreover, government hospitals in developing countries are installing advanced systems to provide better quality treatment for their patients. For instance, in August 2018, Eckert and Ziegler BEBIG delivered and installed SagiNova HDR afterloader at BP Koirala Memorial Cancer Hospital of Nepal. SagiNova is suitable for interstitial breast implants. Hence, the use of such brachytherapy systems by hospitals is expected to fuel market growth.

Market players entering into strategic initiatives such as collaborations and partnerships are anticipated to propel the demand over the next few years. For instance, in July 2018, RaySearch partnered with Eckert and Ziegler BEBIG to integrate SagiNova with the RayCare oncology information system and RayStation treatment planning system to improve treatment outcomes during brachytherapy.

An increase in funding initiatives for HDR units in medical centers by organizations is estimated to drive the market. For instance, in April 2019, OSJ Charities Trust Fund collaborated with the National Federation of Italian Canadians to donate SagiNova for Santo Spirito Hospital as an alternative to external beam radiation therapy for a targeted approach and shorter treatment time.

Favorable reimbursement policies for oncologists, surgeons, and hospitals are expected to fuel market growth. For instance, HDR brachytherapy offers USD 11,000 as Medicare reimbursement for five days treatment period according to the coding issued by Centers for Medicare and Medicaid Services (CMS).

Breast Cancer Brachytherapy Market Report Highlights:

• HDR brachytherapy dominated the market in 2024 and is also projected to be the fastest-growing technology segment over the forecast period
• Factors such as rapid delivery of radiation, accuracy, and precise tumor-specific dose delivery in a shorter period of time are expected to drive the segment
• North America has dominated the market in 2024 owing to the presence of key players and increasing adoption of the therapy by oncology centers and hospitals
• In Asia Pacific, the market is estimated to grow fast over the forecast period due to high unmet needs and growth opportunities for investors and companies to expand their presence in the region.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Technology
  • 1.2.2. Product
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Breast Cancer Brachytherapy Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Breast Cancer Brachytherapy Market: Technology Business Analysis

• 4.1. Technology Market Share, 2024 & 2030
• 4.2. Technology Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Technology, 2018 to 2030 (USD Million)
• 4.4. High Dose Rate (HDR)
  • 4.4.1. High Dose Rate (HDR) Market, 2018 - 2030 (USD Million)
• 4.5. Low Dose Rate (LDR)
  • 4.5.1. Low Dose Rate (LDR) Market, 2018 - 2030 (USD Million)

Chapter 5. Breast Cancer Brachytherapy Market: Product Business Analysis

• 5.1. Product Market Share, 2024 & 2030
• 5.2. Product Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 5.4. Applicators and Afterloaders
  • 5.4.1. Applicators and Afterloaders Market, 2018 - 2030 (USD Million)
• 5.5. Electronic Brachytherapy
  • 5.5.1. Electronic Brachytherapy Market, 2018 - 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Breast Cancer Brachytherapy Market: Regional Estimates & Trend Analysis by Technology and Product

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.4. North America
  • 6.4.1. North America Breast Cancer Brachytherapy Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Regulatory Framework
    • 6.4.2.3. Competitive Insights
    • 6.4.2.4. U.S. Breast Cancer Brachytherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Regulatory Framework
    • 6.4.3.3. Competitive Insights
    • 6.4.3.4. Canada Breast Cancer Brachytherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Regulatory Framework
    • 6.4.4.3. Competitive Insights
    • 6.4.4.4. Mexico Breast Cancer Brachytherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Breast Cancer Brachytherapy Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Regulatory Framework
    • 6.5.2.3. Competitive Insights
    • 6.5.2.4. UK Breast Cancer Brachytherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Regulatory Framework
    • 6.5.3.3. Competitive Insights
    • 6.5.3.4. Germany Breast Cancer Brachytherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Regulatory Framework
    • 6.5.4.3. Competitive Insights
    • 6.5.4.4. France Breast Cancer Brachytherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Regulatory Framework
    • 6.5.5.3. Competitive Insights
    • 6.5.5.4. Italy Breast Cancer Brachytherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Regulatory Framework
    • 6.5.6.3. Competitive Insights
    • 6.5.6.4. Spain Breast Cancer Brachytherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Norway
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Regulatory Framework
    • 6.5.7.3. Competitive Insights
    • 6.5.7.4. Norway Breast Cancer Brachytherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Denmark
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Regulatory Framework
    • 6.5.8.3. Competitive Insights
    • 6.5.8.4. Denmark Breast Cancer Brachytherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. Sweden
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Regulatory Framework
    • 6.5.9.3. Competitive Insights
    • 6.5.9.4. Sweden Breast Cancer Brachytherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Breast Cancer Brachytherapy Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Regulatory Framework
    • 6.6.2.3. Competitive Insights
    • 6.6.2.4. Japan Breast Cancer Brachytherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Regulatory Framework
    • 6.6.3.3. Competitive Insights
    • 6.6.3.4. China Breast Cancer Brachytherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Regulatory Framework
    • 6.6.4.3. Competitive Insights
    • 6.6.4.4. India Breast Cancer Brachytherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Regulatory Framework
    • 6.6.5.3. Competitive Insights
    • 6.6.5.4. South Korea Breast Cancer Brachytherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. Australia
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Regulatory Framework
    • 6.6.6.3. Competitive Insights
    • 6.6.6.4. Australia Breast Cancer Brachytherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Regulatory Framework
    • 6.6.7.3. Competitive Insights
    • 6.6.7.4. Thailand Breast Cancer Brachytherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Breast Cancer Brachytherapy Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Regulatory Framework
    • 6.7.2.3. Competitive Insights
    • 6.7.2.4. Brazil Breast Cancer Brachytherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Regulatory Framework
    • 6.7.3.3. Competitive Insights
    • 6.7.3.4. Argentina Breast Cancer Brachytherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.8. MEA
  • 6.8.1. MEA Breast Cancer Brachytherapy Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Regulatory Framework
    • 6.8.2.3. Competitive Insights
    • 6.8.2.4. South Africa Breast Cancer Brachytherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Regulatory Framework
    • 6.8.3.3. Competitive Insights
    • 6.8.3.4. Saudi Arabia Breast Cancer Brachytherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Regulatory Framework
    • 6.8.4.3. Competitive Insights
    • 6.8.4.4. UAE Breast Cancer Brachytherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Regulatory Framework
    • 6.8.5.3. Competitive Insights
    • 6.8.5.4. Kuwait Breast Cancer Brachytherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. Eckert & Ziegler BEBIG
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Elekta
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Varian Medical Systems, Inc.
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Hologic, Inc.
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Merit Medical Systems
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. BD
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives